What was approved and why it matters
Hovilpri (pritelivir) is the first helicase primase inhibitor, an oral treatment for immunocompromised adults whose herpes simplex lesions do not respond to standard antivirals. Many of these patients today rely on intravenous drugs with substantial risks.
Frequently asked questions
When was pritelivir approved?
The FDA approved Hovilpri (pritelivir) on 9 October 2026 for refractory mucocutaneous herpes simplex lesions in immunocompromised adults.
How effective is Hovilpri?
In PRIOH-1, 63% of patients had all lesions healed by day 28 against 34% on investigator's choice of standard options, and 82% against 42% by day 42.
What are Hovilpri's projected sales?
Zaash Labs' base case is about USD 54 million of US net revenue in 2031. Price has not been disclosed.
Figures are company reported or from published sources unless marked as Zaash Labs estimates. Sources are listed in the executive summary and the full report. Market research to support business decisions; not investment advice.